$BRGX
BIOREGENX, INC. Stock $brgx

$brgx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000168316824008044 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$596.0K	$3.690K
YoY Change		16052.76%	-67.29%
Cost Of Revenue		$114.4K	$0.00
YoY Change			-100.0%
Gross Profit		$481.6K	$3.690K
YoY Change		12952.79%	-63.75%
Gross Profit Margin		80.81%	100.0%
Selling, General & Admin		$236.3K	$3.850K
YoY Change		6037.12%	-64.65%
% of Gross Profit		49.06%	104.34%
Research & Development		$0.00	$80.78K
YoY Change		-100.0%
% of Gross Profit		0.0%	2189.19%
Depreciation & Amortization		$12.38K	$4.450K
YoY Change		178.13%	0.0%
% of Gross Profit		2.57%	120.6%
Operating Expenses		$809.0K	$5.335K
YoY Change		15063.17%	-56.87%
Operating Profit		-$327.3K	-$1.645K
YoY Change		19797.08%	-24.89%
Interest Expense			$2.046K
YoY Change
% of Operating Profit
Other Income/Expense, Net		-$67.55K	-$2.046K
YoY Change		3201.71%
Pretax Income			-$3.691K
YoY Change			68.54%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$394.9K	-$3.691K
YoY Change		10597.91%	68.54%
Net Earnings / Revenue		-66.25%	-100.03%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share		$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	956.5M shares	956.5M shares	276.8M shares
Diluted Shares Outstanding		956.5M shares	269.7M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$760.00
YoY Change		-50.65%
Cash & Equivalents	$70.08K	$758.00
Short-Term Investments
Other Short-Term Assets	$73.32K
YoY Change
Inventory	$158.7K
Prepaid Expenses	$5.162K
Receivables	$19.44K
Other Receivables
Total Short-Term Assets	$371.0K	$758.00
YoY Change	48849.74%	-50.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$213.1K
YoY Change
Goodwill	$7.106M
YoY Change
Intangibles
YoY Change
Long-Term Investments		$200.00
YoY Change		-99.05%
Other Assets	$0.00
YoY Change
Total Long-Term Assets	$16.99M	$33.22K
YoY Change	51040.25%	-44.59%
TOTAL ASSETS
Total Short-Term Assets	$371.0K	$758.00
Total Long-Term Assets	$16.99M	$33.22K
Total Assets	$17.36M	$33.98K
YoY Change	50991.39%	-44.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$492.7K	$26.14K
YoY Change	1784.9%	50.49%
Accrued Expenses	$426.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$200.0K
YoY Change		392.61%
Total Short-Term Liabilities	$3.518M	$240.5K
YoY Change	1362.72%	296.72%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change		-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.518M	$240.5K
Total Long-Term Liabilities		$0.00
Total Liabilities	$3.801M	$240.5K
YoY Change	1480.07%	-6.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.17M	-$3.494M
YoY Change	391.41%
Common Stock	$956.5K	$276.8K
YoY Change	245.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.56M	-$206.6K
YoY Change
Total Liabilities & Shareholders Equity	$17.36M	$33.98K
YoY Change	50991.39%	-44.75%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$394.9K	-$3.691K
YoY Change	10597.91%	68.54%
Depreciation, Depletion And Amortization	$12.38K	$4.450K
YoY Change	178.13%	0.0%
Cash From Operating Activities		-$1.610K
YoY Change		-100.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.690K
YoY Change		-100.08%
NET CHANGE
Cash From Operating Activities		-1.610K
Cash From Investing Activities		0.000
Cash From Financing Activities		1.690K
Net Change In Cash		80.00
YoY Change		-100.0%
FREE CASH FLOW
Cash From Operating Activities		-$1.610K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001593184
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19732	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2798005	usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	42979	usd
	us-gaap	Advertising Expense AdvertisingExpense	46378	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80781	usd
CY2024Q3	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2023Q4	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	963215	usd
CY2023	us-gaap	Interest Expense InterestExpense	292190	usd
CY2024Q3	us-gaap	Payments For Rent PaymentsForRent	5175	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	5175	usd
	us-gaap	Payments For Rent PaymentsForRent	15525	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	213516	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent		usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity File Number EntityFileNumber	000-56345
	dei	Entity Registrant Name EntityRegistrantName	BIOREGENX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-1912453
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7407 Ziegler Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chattanooga
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37421
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	770-4067
	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	956530100	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70081	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125402	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19442	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	104581	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	158726	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	217529	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	122790	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	371039	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	652664	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	213116	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13723	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9671687	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49363	usd
CY2024Q3	us-gaap	Goodwill Goodwill	7105522	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	150000	usd
CY2024Q3	us-gaap	Assets Assets	17361364	usd
CY2023Q4	us-gaap	Assets Assets	865750	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	492713	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	158726	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	217529	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5162	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62467	usd
CY2024Q3	brgx	Inventory Deposits InventoryDeposits	44309	usd
CY2023Q4	brgx	Inventory Deposits InventoryDeposits	0	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	73319	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	142685	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	122790	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	241695	usd
CY2024Q3	brgx	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	178647	usd
CY2023Q4	brgx	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	213516	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	426725	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	346677	usd
CY2024Q3	brgx	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	383906	usd
CY2023Q4	brgx	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	292190	usd
CY2024Q3	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
CY2023Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	322500	usd
CY2024Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	875475	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	375681	usd
CY2024Q3	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2023Q4	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	963215	usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	165574	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	354203	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3518334	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2787177	usd
CY2024Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	282260	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	150000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	3800594	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2937177	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	956530100	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	956530100	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	770833296	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	770833296	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	956530	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	770833	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29777603	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9676656	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17171424	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12517978	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1943	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-942	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	13560770	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17361364	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	865750	usd
CY2024Q3	brgx	Gross Revenues GrossRevenues	596510	usd
CY2023Q3	brgx	Gross Revenues GrossRevenues	800149	usd
	brgx	Gross Revenues GrossRevenues	2138993	usd
	brgx	Gross Revenues GrossRevenues	2786588	usd
CY2024Q3	brgx	Sales Returns SalesReturns	473	usd
CY2023Q3	brgx	Sales Returns SalesReturns	5605	usd
	brgx	Sales Returns SalesReturns	259376	usd
	brgx	Sales Returns SalesReturns	53181	usd
CY2024Q3	us-gaap	Revenues Revenues	596037	usd
CY2023Q3	us-gaap	Revenues Revenues	794544	usd
	us-gaap	Revenues Revenues	1879617	usd
	us-gaap	Revenues Revenues	2733407	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	114389	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	223343	usd
	us-gaap	Cost Of Revenue CostOfRevenue	543933	usd
	us-gaap	Cost Of Revenue CostOfRevenue	800004	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	481648	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	571201	usd
	us-gaap	Gross Profit GrossProfit	1335684	usd
	us-gaap	Gross Profit GrossProfit	1933403	usd
CY2024Q3	us-gaap	Incentive Fee Expense IncentiveFeeExpense	10587	usd
CY2023Q3	us-gaap	Incentive Fee Expense IncentiveFeeExpense	76152	usd
	us-gaap	Incentive Fee Expense IncentiveFeeExpense	177833	usd
	us-gaap	Incentive Fee Expense IncentiveFeeExpense	395752	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	236279	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2963602	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3982443	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4734930	usd
CY2024Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	562089	usd
CY2023Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1621948	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	808955	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3039754	usd
	us-gaap	Operating Expenses OperatingExpenses	5782224	usd
	us-gaap	Operating Expenses OperatingExpenses	5130682	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-327307	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2468553	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4446540	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3197279	usd
CY2024Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	67553	usd
CY2023Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	50482	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	206906	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	146055	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-67553	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-50482	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-206906	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-146055	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-394860	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2519035	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4653446	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3343334	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	956530100	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	956530100	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	621921192	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	621921192	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	928777082	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	928777082	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	620755525	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	620755525	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-394860	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2519035	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4653446	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3343334	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2561	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1001	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19732	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-397421	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2519035	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4654447	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3323602	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2527938	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	815053	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2238482	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3343334	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	757403	usd
	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	1491833	usd
	brgx	Stock Issued During Period Fair Value Of Common Shares And Warrants Issued For Refunds StockIssuedDuringPeriodFairValueOfCommonSharesAndWarrantsIssuedForRefunds	41551	usd
	brgx	Issuance Of Common Shares And Warrants As Loan Incentive IssuanceOfCommonSharesAndWarrantsAsLoanIncentive	21263	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10656000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7318594	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4653446	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1001	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	13560770	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	63210	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2238482	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2519035	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2798005	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	14221236	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67834	usd
CY2024Q3	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services Forfeitures Net StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServicesForfeituresNet	-331303	usd
CY2024Q3	brgx	Issuance Of Common Shares And Warrants As Loan Incentive IssuanceOfCommonSharesAndWarrantsAsLoanIncentive	424	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-394860	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2561	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	13560770	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4653446	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3343334	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1644726	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3580	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	33410	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1491833	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	757403	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2238482	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	2923	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	19351	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-85139	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1442	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-58803	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2412	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-82362	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	123254	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	251018	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-358815	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-34869	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-69871	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	23273	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	144116	usd
	brgx	Increase Decrease In Accrued Interest Related Parties IncreaseDecreaseInAccruedInterestRelatedParties	91716	usd
	brgx	Increase Decrease In Accrued Interest Related Parties IncreaseDecreaseInAccruedInterestRelatedParties	53049	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-166429	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	182776	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-312787	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1269417	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189390	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2652	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1445	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-190597	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-39770	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-195312	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	456754	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	71211	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	32079	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	815053	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	449063	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	690952	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19732	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-55321	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-558733	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125402	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	616696	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70081	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57963	usd
	us-gaap	Interest Paid Net InterestPaidNet	70430	usd
	us-gaap	Interest Paid Net InterestPaidNet	67397	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	10656000	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	0	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	7318594	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	22200	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts FairValueOfCommonStockAndWarrantsIssuedForLoanFeesOffsetToLoanDiscounts	21263	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts FairValueOfCommonStockAndWarrantsIssuedForLoanFeesOffsetToLoanDiscounts	0	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	150000	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	0	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	30000	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4653446	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-312787	usd
	brgx	Working Capital Deficit WorkingCapitalDeficit	3147295	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70081	usd
CY2024Q3	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zywaGp0wc6M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_861_z1gjRpnL7CYl">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in purchase price allocations, and assumptions made in valuing equity instruments issued for services and acquisitions. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q3	brgx	Gross Revenues GrossRevenues	596510	usd
CY2023Q3	brgx	Gross Revenues GrossRevenues	800149	usd
	brgx	Gross Revenues GrossRevenues	2138993	usd
	brgx	Gross Revenues GrossRevenues	2786588	usd
CY2024Q3	brgx	Gross Revenues GrossRevenues	596510	usd
CY2023Q3	brgx	Gross Revenues GrossRevenues	800149	usd
	brgx	Gross Revenues GrossRevenues	2138993	usd
	brgx	Gross Revenues GrossRevenues	2786588	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	354203	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	193811	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	330645	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	236684	usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	165574	usd
CY2024Q3	us-gaap	Advertising Expense AdvertisingExpense	18299	usd
	us-gaap	Advertising Expense AdvertisingExpense	92086	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14543	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	175072	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zWMWrwkMg2ll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zI5nETC9krf6">Reclassifications</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current period, the Company reclassified $<span id="xdx_902_ecustom--AccruedExpensesReclassifiedAmount_iI_c20231231_z8KJElt10ztl" title="Accrued expenses reclassified amount">72,000</span> of return reserves previously reflected as an offset to accounts receivable at December 31, 2023 to accrued expenses to conform to current period classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	brgx	Accrued Expenses Reclassified Amount AccruedExpensesReclassifiedAmount	72000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11293636	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49363	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1621949	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9671687	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49363	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	562089	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1621949	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	614014	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2248355	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2248355	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2248355	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2248355	usd
CY2024Q3	brgx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	64253	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12377	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1193	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22778	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3580	usd
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2024Q3	brgx	Warrants Exercisable WarrantsExercisable	0	usd
CY2024Q3	us-gaap	Loans Payable LoansPayable	1157735	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	525681	usd
CY2024Q3	us-gaap	Loans Payable Current LoansPayableCurrent	875475	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	375681	usd
CY2024Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	282260	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	150000	usd
	us-gaap	Interest Expense InterestExpense	383906	usd
	us-gaap	Payments For Rent PaymentsForRent	15525	usd
CY2024Q3	us-gaap	Payments For Royalties PaymentsForRoyalties	3405	usd
CY2023Q3	us-gaap	Payments For Royalties PaymentsForRoyalties	3162	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	8941	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	10487	usd
	us-gaap	Legal Fees LegalFees	5000	usd
	us-gaap	Legal Fees LegalFees	53189	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	178647	usd
CY2023Q3	brgx	Gross Revenues GrossRevenues	800149	usd
CY2023Q3	brgx	Sales Returns SalesReturns	5605	usd
CY2023Q3	us-gaap	Revenues Revenues	794544	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2963602	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2519035	usd
	brgx	Gross Revenues GrossRevenues	2786588	usd
	brgx	Sales Returns SalesReturns	53181	usd
	us-gaap	Revenues Revenues	2733407	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4734930	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3343334	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2798005	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3343334	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1269417	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	690952	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-008044-index-headers.html	Edgar Link	pending
0001683168-24-008044-index.html	Edgar Link	pending
0001683168-24-008044.txt	Edgar Link	pending
0001683168-24-008044-xbrl.zip	Edgar Link	pending
bioregenx_ex3100.htm	Edgar Link	pending
bioregenx_ex3200.htm	Edgar Link	pending
bioregenx_i10q-093024.htm	Edgar Link	pending
brgx-20240930.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
brgx-20240930_cal.xml	Edgar Link	unprocessable
brgx-20240930_def.xml	Edgar Link	unprocessable
brgx-20240930_lab.xml	Edgar Link	unprocessable
brgx-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bioregenx_i10q-093024_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRGX
BIOREGENX, INC. Stock $brgx

2024 Q4 Form 10-Q Financial Statement

#000168316824008044 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRGX BIOREGENX, INC. Stock $brgx

2024 Q4 Form 10-Q Financial Statement

#000168316824008044 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRGX
BIOREGENX, INC. Stock $brgx